

**Alaska Medicaid Pharmacy and Therapeutics Committee Meeting
November 20, 2020**

Frontier Building, 3601 C Street; Room 880/890

Please note, as a result of COVID-19 this meeting will be available via teleconference only

Agenda

Public Call in: 1.800.315.6338. Access code **24251#**

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment**

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where ****new information exists** and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

***New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.*

4. Class Review, Discussion & Vote

AK Treatment Class	Drug Class	Status
Cystic Fibrosis	CFTR Potentiator Agents	BLUE**
	Antibiotics, Inhaled	GREEN
	Pancreatic Enzymes	GREEN
Central Nervous System	Multiple Sclerosis Agents	RED**
	Stimulants & Related Agents	GREEN
	Sedative Hypnotics	RED**
	Anticonvulsants	RED**
	Antipsychotics – Atypical	RED**
	Antidepressants	RED**
	Alzheimer’s Agents	GREEN
Analgesics	NSAIDS	RED**
	Analgesics, Opioid – Short Acting	RED**
	Analgesics, Opioid – Long-Acting	BLUE**
	Neuropathic Pain	BLUE**
	Antimigraine Agents	RED**
	Skeletal Muscle Relaxants	BLUE**
	Restless Leg Syndrome (RLS)	GREEN
Substance Dependence	Smoking Cessation Products	BLUE**
	Opioid Dependence	BLUE**
	Opioid Reversal Agents	GREEN
Antiviral Monoclonal Antibodies	Respiratory Syncytial Virus	GREEN
Specialty Drug Class	Review Criteria for Designation	GREEN

5. **Break as needed** – 15 minutes
6. **Review minutes** from **September 2020** meeting
7. **Comments from Committee Members or Chair**
8. **Adjourn**

Next Meeting Date: January 15, 2021